Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue
Total revenue	$ 469,745	$ 829,716
Operating expenses
Cost of products sold	291,997	554,054
Cost of services	30,562	104,984
Research and development, net	2,316,441	2,813,491
General and administrative	2,625,053	2,663,657
Sales and marketing	1,051,432	899,252
Impairment of right-of-use asset		55,496
Total operating expenses	6,315,485	7,090,934
Operating loss	(5,845,740)	(6,261,218)
Other (expense) income
Warrant inducement expense		(7,755,541)
Interest and other income	3,121	4,925
Interest expense	(1,269,581)	(1,164,982)
Foreign currency transaction gains	198,740	427,615
Change in fair value of derivative financial instruments	109,744	(101,390)
Total other expense	(957,976)	(8,589,373)
Loss before income taxes	(6,803,716)	(14,850,591)
Provision for income taxes
Net loss	(6,803,716)	(14,850,591)
Net loss available to common stockholders	$ (6,803,716)	$ (14,850,591)
Net loss per common share - basic and diluted (in Dollars per share)	$ (0.15)	$ (0.5)
Weighted average shares outstanding - basic and diluted (in Shares)	46,483,694	29,485,067
Net loss	$ (6,803,716)	$ (14,850,591)
Other comprehensive loss - foreign currency translation	(483,849)	(1,078,479)
Comprehensive loss	(7,287,565)	(15,929,070)
Product sales
Revenue
Total revenue	366,052	613,918
Laboratory services
Revenue
Total revenue	42,929	97,726
Collaboration revenue
Revenue
Total revenue	$ 60,764	$ 118,072